These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21086021)

  • 41. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
    Lin P; Sinha U; Betz A
    Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
    Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome.
    Frere C; Laine M; Lemesle G; Morange PE; Paganelli F; Dignat-George F; Resseguier N; Guieu R; Camoin-Jau L; Bonello L
    Platelets; 2019; 30(1):105-111. PubMed ID: 29172822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.
    Anand SX; Kim MC; Kamran M; Sharma SK; Kini AS; Fareed J; Hoppensteadt DA; Carbon F; Cavusoglu E; Varon D; Viles-Gonzalez JF; Badimon JJ; Marmur JD
    Am J Cardiol; 2007 Aug; 100(3):417-24. PubMed ID: 17659921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase.
    Welsh RC; Westerhout CM; Buller CE; O'Neill B; Gordon P; Armstrong PW
    J Thromb Thrombolysis; 2012 Jul; 34(1):126-31. PubMed ID: 22362559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris.
    Rabah MM; Premmereur J; Graham M; Fareed J; Hoppensteadt DA; Grines LL; Grines CL
    Am J Cardiol; 1999 Dec; 84(12):1391-5. PubMed ID: 10606110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
    Kaiser B; Hoppensteadt DA; Jeske W; Wun TC; Fareed J
    Thromb Res; 1994 Sep; 75(6):609-16. PubMed ID: 7831680
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
    Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
    Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
    Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa.
    Al-Tamimi M; Grigoriadis G; Tran H; Paul E; Servadei P; Berndt MC; Gardiner EE; Andrews RK
    Blood; 2011 Apr; 117(14):3912-20. PubMed ID: 21252089
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery.
    Hakki SI; Fareed J; Hoppensteadt DA; Abdullah H; Camblin J; Nasseri AF; Hamadeh O; Wright T
    Clin Appl Thromb Hemost; 2000 Oct; 6(4):206-12. PubMed ID: 11030526
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
    Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
    J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome].
    Slavina NN; Averkov OV; Gratsianskiĭ NA
    Kardiologiia; 2005; 45(12):11-6. PubMed ID: 16353041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects on platelet function of a direct acting antagonist of coagulation factor Xa.
    Ringwala SM; Dibattiste PM; Schneider DJ
    J Thromb Thrombolysis; 2012 Oct; 34(3):291-6. PubMed ID: 22528328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factor Xa inactivation in acute coronary syndrome.
    Barantke M; Bonnemeier H
    Curr Pharm Des; 2008; 14(12):1186-90. PubMed ID: 18473865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
    Brophy DF; Martin EJ; Best AM; Gehr TW; Carr ME
    J Thromb Haemost; 2004 Aug; 2(8):1299-304. PubMed ID: 15304034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.